Recent developments include capital raising through a public offering and a registered direct offering, revenue growth with some net income decline, and strategic expansion efforts.

• Raytech Holding Limited priced a public offering of 25,985,000 ordinary shares at $0.20 per share on July 1, 2025, raising net proceeds for acquisitions, business expansion, marketing, and working capital [N1].
• The company reported a 31.0% revenue increase but declines in net income for the six months ended September 30, 2024, indicating mixed operational performance [N2].
• On June 29, 2026, Raytech closed a registered direct offering of 3,149,832 ordinary shares at $1.97 per share, raising approximately $6.2 million gross proceeds to support corporate purposes and strategic expansion into personal health care electronics [S2].

Raytech has demonstrated revenue growth with a 31.0% increase reported for the six months ended September 30, 2024, and has successfully raised capital through multiple offerings to support expansion and acquisitions. The company is actively addressing internal control weaknesses and maintains a robust liquidity position, which supports operational stability and strategic initiatives.

The company exhibits significant customer and supplier concentration risks, with one customer accounting for over 60% of revenues and a related party supplier comprising a large portion of purchases. Material weaknesses in internal controls over financial reporting present risks to accurate financial disclosure. The lack of detailed sector and industry information limits external assessment of competitive positioning and market risks.

Raytech's moat is not explicitly detailed in the available disclosures. The company operates with significant customer and supplier concentration, which may indicate reliance on key partners. Its strategic focus includes expansion into personal health care electronics and acquisitions, but competitive advantages or barriers to entry are not described in the public information.

• Customer Concentration Risk: One major customer accounted for 62.5% of total revenues for the fiscal year ended March 31, 2026, which may expose the company to revenue volatility if this relationship changes.
• Supplier Concentration Risk: Zhongshan Raytech, a related party, accounted for 62.1% of total purchases for the fiscal year ended March 31, 2026, indicating dependency on a limited number of suppliers.
• Internal Control Weaknesses: Material weaknesses in internal control over financial reporting were identified related to segregation of duties and insufficient financial reporting personnel expertise, which could affect financial accuracy and compliance.
• Market and Currency Risks: The company is exposed to interest rate and foreign currency risks, although foreign exchange risk is minimal due to the HKD peg to USD.

• Raytech Holding Ltd is a publicly reporting company with recent SEC filings including a 20-F annual report filed on 2026-07-31 and a 6-K quarterly report filed on 2026-06-29.
• As of March 31, 2026, Raytech reported cash and cash equivalents of approximately $9.95 million USD and current assets of about $21.5 million USD, with current liabilities of approximately $9.12 million USD, resulting in a current ratio of 2.36 and a cash ratio of 1.09, indicating liquidity.
• For the fiscal year ended March 31, 2026, Raytech reported revenues of approximately $18.2 million USD and net income of about $2.13 million USD.
• Basic and diluted earnings per share for the fiscal year ended March 31, 2026 were 7.19 HKD per share.
• Raytech completed a public offering on July 1, 2025, issuing 25,985,000 ordinary shares at $0.20 per share, raising net proceeds used for potential acquisitions, trading business expansion, marketing, sales, product development, and general working capital.
• On June 29, 2026, Raytech closed a registered direct offering of 3,149,832 ordinary shares at $1.97 per share, raising approximately $6.2 million USD gross proceeds for general corporate and working capital purposes, strategic expansion into personal health care electronics, and integration costs related to the acquisition of Worry Free Group (Hong Kong) Limited.
• Raytech's business involves distributors representing and selling brands from Japan, the U.S., UK, Europe, and Australia, with customer concentration risk noted: one major customer accounted for 62.5% of total revenues for the year ended March 31, 2026.
• Supplier concentration risk exists with Zhongshan Raytech accounting for 62.1% of total purchases for the year ended March 31, 2026, and related parties comprising significant portions of accounts payable.
• Raytech has identified material weaknesses in internal control over financial reporting related to segregation of duties and financial reporting personnel expertise, and is implementing measures to address these weaknesses.
• The company maintains a cybersecurity risk management program overseen by the CFO and Audit Committee, focusing on risk mitigation, compliance, and employee training.
• Raytech does not use financial instruments for speculative trading and is exposed primarily to interest rate and foreign currency risks, with minimal foreign exchange risk due to HKD peg to USD.